Robert Adelman
MD DIRECTOR
Apellis
United States of America
Biography
Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. He led Fund I's investments into Aragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Johnson and Johnson. He also led the investment into Seragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Genentech/Roche. Dr. Adelman co-led Fund I's investments with Dr. Goodman into Solstice Biologics and Heart Metabolics and currently serves on the Board of both companies.
Research Interest
Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. He led Fund I's investments into Aragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Johnson and Johnson. He also led the investment into Seragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Genentech/Roche. Dr. Adelman co-led Fund I's investments with Dr. Goodman into Solstice Biologics and Heart Metabolics and currently serves on the Board of both companies.
